This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Richy F et al. (2005) Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int 76: 176–186
Lucky MM et al.(2003) Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis. Obstet Gynecol 101: 711–721
Hahn, TJ et al. (1979) Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25 hydroxy vitamin D administration. J Clin Invest 63: 655–663
Holick MF (2006) The role of vitamin D in bone health and fracture prevention. Curr Osteoporosis Rep 4: 96–102
Acknowledgements
The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Hahn, B., Hahn, T. Alendronate versus alfacalcidol in the prevention of glucocorticoid-induced bone loss. Nat Rev Rheumatol 3, 10–11 (2007). https://doi.org/10.1038/ncprheum0370
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0370